Anastasia Semykina is a Professor of Economics and Deputy Dean (Research and Innovation) at RMIT University's School of Economics, Finance & Marketing. She holds a PhD from Michigan State University (2006) and previously served as Charles and Joan Haworth Professor of Economics at Florida State University. Her expertise spans theoretical and applied econometrics, with a focus on panel data models, missing data estimation, and their application in labor economics, education economics, transition economies, and economic psychology. She teaches advanced econometrics and microeconomics courses at both undergraduate and graduate levels. Research Interests: Theoretical and Applied Econometrics Labor Economics Economics of Education Transition Economies Economics and Psychology Health Economics Her recent publications address topics such as panel data methodologies, healthcare cost-effectiveness analysis, and educational policy evaluation. She is actively involved in supervising PhD and Master's research students in econometrics and applied economics.
Shasha Chong is an Assistant Professor of Chemistry at the California Institute of Technology and a Ronald and JoAnne Willens Scholar. She earned her B.S. from the University of Science & Technology of China (2008) and Ph.D. from Harvard University (2014). Her research bridges chemistry, physics, and biology to investigate the molecular mechanisms of cellular processes, focusing on intrinsically disordered regions (IDRs) in transcription proteins. Research Focus: IDRs in transcriptional regulation, cancer biology, liquid-liquid phase separation, and single-molecule imaging techniques. Grants & Awards: CCE Innovation Award (2024), ALSF Innovation Grant, Mallinckrodt Research Grant, Margaret E. Early Medical Research Trust Grant. Collaborations: Caltech-City of Hope Biomedical Research Initiative Grant (2025). Teaching: Co-instructor for courses like Biochemistry Laboratory (Ch 11) and Advanced Topics in Biochemistry (BMB/Bi/Ch 174). Labs & Teams: Leads the Chong Laboratory at Caltech, focusing on interdisciplinary approaches combining single-molecule imaging, genome editing, and bioinformatics.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
John P. O'Doherty serves as the Fletcher Jones Professor of Decision Neuroscience within Caltech's Division of Humanities and Social Sciences, holding continuous faculty appointments since 2004 (Assistant Professor 2004-07, Associate Professor 2007-09, Professor 2009-present, Fletcher Jones Professor 2021-present). He previously directed the Caltech Brain Imaging Center (2013-17) and maintains affiliations with the T&C Chen Center for Social and Decision Neuroscience. His educational background includes a B.A. from University of Dublin, Trinity College (1996) and D.Phil. from University of Oxford (2000). His research focuses on computational and neural mechanisms of reward-based learning and decision-making , employing fMRI, intracranial recordings, and mathematical modeling to investigate how the brain solves complex decision problems through evolutionarily conserved algorithms. Key areas include Reinforcement learning systems (model-based/model-free arbitration) Observational and social learning mechanisms Neural representation of value, risk, and uncertainty Computational phenotyping of mental disorders Temporal dynamics of goal persistence Analysis of his 2023-2025 publications reveals dominant trends in computational psychiatry (problem gambling, autism traits), hierarchical decision-making, and neuroeconomic modeling of social behavior. His work consistently integrates cross-species computational frameworks with human neuroimaging to identify transdiagnostic mechanisms. While specific awards beyond his endowed professorship aren't detailed, his leadership as Brain Imaging Center Director and prolific high-impact publications demonstrate significant recognition. Current advising includes graduate researcher Sneha Aenugu on goal-persistence projects, with administrative support from Mary A. Martin (mmartin@caltech.edu). His active research program continues to pioneer computational approaches to understanding decision pathologies.
Marc V Fuccillo is an Associate Professor of Neuroscience at the Perelman School of Medicine, University of Pennsylvania, where he leads a research laboratory focused on understanding the neural circuit mechanisms underlying behavioral control. His work bridges molecular, synaptic, and behavioral approaches to investigate how striatal circuits regulate mouse behavior from simple motor patterns to complex goal-directed actions. Fuccillo holds dual appointments in the Neuroscience and Cell and Molecular Biology Graduate Groups at Penn and maintains an active laboratory investigating the synaptic and circuit basis of neuropsychiatric disorders. Education: B.A. in Molecular and Cellular Biology and Music Performance (Violin) from Brown University (1998) Ph.D. in Developmental Genetics from New York University School of Medicine (2007) M.D. from New York University School of Medicine (2008) Fuccillo's research centers on the synaptic and circuit mechanisms of behavioral control, with particular emphasis on striatal circuits. His laboratory employs a range of technologies including mouse genetics, in vitro electrophysiology, in vivo imaging, and quantitative behavioral analysis to explore how neural circuits of the striatum regulate behavior and how disruptions in these circuits contribute to neuropsychiatric disorders. His work has particularly focused on autism-associated abnormalities in behavioral control, examining how synaptic adhesion molecules like neuroligins and neurexins shape circuit function and behavior, with significant findings regarding D1 dopamine receptor positive medium spiny neurons in the nucleus accumbens. Analysis of Fuccillo's recent publications reveals a strong focus on striatal circuit function across multiple dimensions. His work spans molecular neuroscience (examining synaptic adhesion molecules), cellular physiology (studying specific neuron types in striatal circuits), systems neuroscience (mapping circuit connectivity), and behavioral neuroscience (quantifying motor learning and decision-making). A unifying theme is how disruptions in specific molecular pathways lead to circuit-level abnormalities that manifest as behavioral phenotypes relevant to neuropsychiatric disorders, with particular attention to autism, OCD, and schizophrenia models. Scientific Recognition: Publications in high-impact journals including Nature Neuroscience, Current Biology, Cell Reports, and Neuron Research supported by multiple NIH grants including NIMH F32, NIMH K01, and HHMI Gilliam Fellowship awards for lab members Fuccillo actively mentors a diverse group of trainees including postdoctoral fellows, graduate students, and undergraduates. His laboratory has produced numerous successful alumni who have gone on to faculty positions, medical residencies, and graduate programs at prestigious institutions. His mentoring approach emphasizes technical skill development across multiple neuroscience disciplines while fostering independent scientific thinking. Current research in his lab is supported by NIH funding focused on understanding the molecular architecture of striatal circuits and their role in behavioral control, with three major research directions exploring molecular logic of striatal circuits, circuit mechanisms of behavioral control, and striatal dysfunction in neuropsychiatric disease models. The Fuccillo Laboratory operates within the Department of Neuroscience at the University of Pennsylvania, with access to state-of-the-art facilities for molecular, electrophysiological, imaging, and behavioral neuroscience research. The lab maintains active collaborations with other neuroscience research groups at Penn and beyond, creating a rich intellectual environment for studying the neural basis of behavior. Current research directions include investigating whether there is a molecular logic to striatal circuit composition, how striatal circuits shape behavioral control, and what mouse models of autism, schizophrenia, and OCD can reveal about striatal circuit dysfunction in disease pathophysiology.
Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.
Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.
John D. Murray is the Gregg L. Engles Associate Professor of Psychological and Brain Sciences at Dartmouth College and an Adjunct Associate Professor of Psychiatry at Yale School of Medicine. He holds a PhD in Physics from Yale University (2013) and a BS in Physics and Mathematics from Yale (2006). His research focuses on computational neuroscience and computational psychiatry, with secondary appointments in Physics and Neuroscience at Yale until 2023. His work integrates computational modeling, neuroimaging, and systems neuroscience to study decision-making processes, cortical organization, and psychiatric disorders. Collaborators include prominent researchers like Dr. John Krystal and Dr. Anticevic. Research interests include hierarchical brain organization, neuroimaging analysis techniques, and pharmacological effects on neural circuits. His lab (Murray Lab) develops computational tools like PsychRNN for cognitive task modeling. Notable contributions include linking transcriptomic data to neuroimaging patterns and modeling LSD’s effects on brain topography. He has been featured in YaleNews and Nature Communications for innovations in mapping mental illness variability and neural circuit dynamics. Grants and collaborations span translational neuroscience, addiction, and PTSD research through partnerships with Yale’s Center for Biomedical Data Science and VA National Center for PTSD. His interdisciplinary approach bridges physics, computer science, and clinical psychiatry to advance understanding of brain function and dysfunction.
Lindsey Draper, MD serves as an Adjunct Instructor in the Roybal Laboratory within the Department of Medicine, Division of Hematology and Oncology at the University of California San Francisco School of Medicine. Her clinical practice focuses on the treatment of patients with recurrent ovarian cancer using systemic therapies including chemotherapy and immunotherapy, with a commitment to evaluating and offering clinical trial opportunities as part of individualized patient care. Dr. Draper completed her educational training with a B.S. in Biology from Juniata College (2010), an M.D. from the University of Maryland School of Medicine (2017), an Internal Medicine Residency at The Mount Sinai Hospital (2022), and is currently completing a Medical Oncology Fellowship at UCSF (2025-2027). Her research interests center on cancer immunotherapy, particularly T cell-based approaches for HPV-associated cancers and ovarian cancer. She investigates engineered T cell therapies targeting viral antigens in cervical and other HPV-related cancers, with a focus on overcoming treatment resistance and improving clinical outcomes through novel immunotherapeutic strategies. Her work bridges fundamental immunological mechanisms with clinical applications, emphasizing the translation of laboratory discoveries into patient treatments. Dr. Draper's publication record demonstrates consistent contributions to the field of cancer immunotherapy, with recent work focusing on TCR-engineered T cells for leukemia and HPV-associated malignancies. Her research trajectory shows increasing sophistication in T cell engineering approaches and a growing emphasis on addressing inflammatory responses and treatment resistance mechanisms. Parker Institute for Cancer Immunotherapy Early Career Research Award: Parker Scholar (2024) Gladstone-UCSF Institute of Genomic Immunology Symbiont Seed Grant for 'Antigen Discovery for Ovarian Cancer' (2024) Conquer Cancer Young Investigator Award, American Society of Clinical Oncology (2024) Women in Cancer Immunotherapy Network Leadership Institute Selected Participant, Society for Immunotherapy of Cancer (2024) Physician-Scientist Fellow, Chan Zuckerberg Biohub - San Francisco (2023-2025) As a physician-scientist, Dr. Draper maintains an active research program while providing clinical care, with particular emphasis on developing novel immunotherapies for gynecologic cancers. Her current fellowship at UCSF and multiple early-career awards indicate strong potential for continued contributions to the field of cancer immunotherapy. Dr. Draper works within the Roybal Laboratory at UCSF, which focuses on innovative approaches to cancer immunotherapy and T cell engineering. Her research intersects with multiple collaborative initiatives at UCSF, including the Parker Institute for Cancer Immunotherapy and the Gladstone-UCSF Institute of Genomic Immunology.
Manuel R. Amieva is a Professor at Stanford University School of Medicine , holding joint appointments in Pediatrics - Infectious Diseases and Microbiology & Immunology . He is also a member of the Maternal & Child Health Research Institute (MCHRI) . His clinical practice at Stanford Medicine Children's Health focuses on pediatric infectious diseases. Education: Medical Education: Stanford University School of Medicine (1997) Fellowship: Stanford University Pediatric Infectious Disease Fellowship (2004) Internship & Residency: Stanford Health Care at Lucile Packard Children's Hospital (1998-1999) Dr. Amieva's research investigates host-pathogen interactions at epithelial barriers, with specific expertise in Helicobacter pylori , Listeria monocytogenes , Salmonella enterica , and Staphylococcus aureus . His lab develops innovative organoid culture systems with controlled polarity to study microbial colonization and oncogenic mechanisms. Key discoveries include: H. pylori's manipulation of epithelial junctions via the CagA protein Listeria's exploitation of cell extrusion sites for invasion Staphylococcus toxin interactions with adherens junctions Gastric stem cell activation by pathogens Recent publication trends show continued leadership in infectious disease mechanisms (2020-2025), with a focus on: Pathogen-specific epithelial breach strategies Organoid modeling of viral/bacterial interactions Redox-dependent host factor regulation Single-cell spatial transcriptomic analyses Multi-institutional educational frameworks His scientific collaborations span disciplines including: Gastric cancer genomics initiatives COVID-19 lung infection models Stem cell-microbe interactions Medical education reform projects Dr. Amieva maintains active clinical research while mentoring students in both the Microbiology & Immunology and Pediatrics programs. His lab at Stanford employs advanced 3D confocal microscopy and organ-on-a-chip technologies to visualize epithelial colonization dynamics.
Rotem Karni, PhD, is an Associate Professor of Genetics at the Perelman School of Medicine, University of Pennsylvania, Philadelphia. He leads a research lab focused on understanding how alternative RNA splicing contributes to cancer and genetic diseases, with a strong emphasis on translating these findings into RNA-based therapies. Karni's lab develops decoy oligonucleotides, small molecules, and splice-switching technologies to modulate splicing factors and enhance immunotherapy. Education BSc in Biological Chemistry from The Hebrew University of Jerusalem (1997) PhD in Biological Chemistry from The Hebrew University of Jerusalem, Israel (2002) Postdoctoral Fellowship at Cold Spring Harbor Laboratory, NY (2002-2007) Karni's research explores the deregulation of alternative splicing in oncogenesis, particularly how splicing factors like RBFOX2 and S6K1 influence metastasis, DNA repair, and immune checkpoint modulation. His team investigates m6A RNA modifications for stabilizing mutant genes, with applications in Duchenne Muscular Dystrophy and pancreatic cancer. The lab's work is commercialized through biotech companies: SKIP Therapeutics, Andlit Therapeutics, and RNAble. Selected Research Trends RNA mis-splicing and neoantigen generation (2025) Splicing factor inhibition for tumor suppression (2023) Metastatic splicing signatures in pancreatic cancer (2023) Immune checkpoint splicing in cancer immunotherapy (2021) m6A modulation for mRNA stabilization (2023) Advising & Collaborations Karni has mentored numerous PhD and postdoctoral researchers, many of whom now hold leadership roles in academia, biotech, and medical institutions globally. His lab collaborates extensively on projects involving RNA innovation, including partnerships with the Institute for RNA Innovation. Contact Department of Genetics & Institute for RNA Innovation, One uCity Square, Room 4018, Philadelphia, PA 19104 Phone: 215-898-5072 Email: Rotem.Karni@Upenn.edu
Sachdev Sidhu is a Research Professor and Entrepreneur in Residence at the University of Waterloo. His research focuses on synthetic antibodies, protein engineering, and biotechnological applications. He leads efforts in developing novel therapeutic antibodies, engineered protein systems, and molecular tools for biomedical research. His work spans cancer therapy, viral infection countermeasures, and regenerative medicine. Sidhu is also involved in translational research, bridging academic discoveries with commercial applications through entrepreneurial ventures. Key research interests include synthetic antibody libraries, CAR T-cell engineering, ubiquitin-based therapeutics, and phage display technologies. He has contributed to advancements in targeted therapies for glioblastoma, leukemia, and ocular diseases. His team develops innovative methods for protein design, such as engineered ubiquitin variants and modular antibody architectures. Publications highlight breakthroughs in antibody-based treatments, including synNotch CAR T cells for glioblastoma and neutralizing antibodies against SARS-CoV-2. His work integrates structural biology, molecular biology, and computational approaches to address complex biomedical challenges. Sidhu collaborates with industry partners to advance technologies into clinical and commercial settings.
About Dr. Pegah Varamini Dr. Pegah Varamini is a Senior Lecturer in Pharmacy and Pharmacology at the Sydney Pharmacy School, University of Sydney, and a Casual Lecturer in Music Education at the Sydney Conservatorium of Music. She leads the Breast Cancer Targeting & Drug Delivery (BCTDD) Group, focusing on innovative drug delivery systems for Triple Negative Breast Cancer (TNBC). Her research integrates nanotechnology, targeted therapy, and translational medicine, supported by prestigious grants including the NBCF Fellowship (2016). Research & Education PharmD (Shiraz University of Medical Sciences) PhD in Pharmaceutical Sciences (University of Queensland) Second PhD in Music Education (University of Sydney Conservatorium of Music) Key Research Interests Her work centers on: Peptide-based targeting strategies using 'Trojan Horse' approaches for TNBC Development of nanomedicine for bone metastasis prevention Clinically relevant preclinical models for personalized breast cancer treatment Collaborations with international institutions (e.g., Harvard Medical School, University of Nantes) Teaching & Supervision Dr. Varamini coordinates Drug Design and Development (PCOL3012/3912) and supervises a multidisciplinary team of HDR students and postdoctoral researchers. Notable current students include PhD candidate Hany Ghaly and MPhil candidates Huimin Shao and Farhana Mollah. Awards & Recognition 2021 Equity Prize 2016 Top 25 Young Researchers of Australia and New Zealand 2018 Fresh Scientist of the Year Recipient of multiple grants totaling over AUD 2M Leadership & Outreach She co-chairs the Nanopharma cluster at Sydney Nano Institute and advises the WHO Global Breast Cancer Initiative. Her work has been featured in media outlets such as SBS Farsi News and NBCF publications.
Dr. Susan Hua is an Associate Professor at the University of Newcastle's School of Biomedical Sciences and Pharmacy, specializing in translational nanopharmaceutics and therapeutic targeting. She established the first translational nanopharmaceutics laboratory in the Hunter region, focusing on drug delivery systems for gastrointestinal, musculoskeletal, and reproductive pathologies. Education: Bachelor of Pharmacy with Honours, University of Queensland (UQ) PhD in Neuroscience and Nanotechnology, UQ Research Interests: Her work centers on using nanotechnology to create targeted drug delivery systems for diseases such as chronic pain, inflammatory conditions, and obstetric complications. Key focuses include oxytocin receptor-targeted liposomes for uterine therapies and localized drug delivery to bypass biological barriers. Awards & Recognition: 2020 DVC(A) Educator Innovation Award 2017 NSW Premier's Early Career Researcher of the Year 2015 HMRI Early Career Researcher of the Year Grants & Collaborations: A/Prof Hua has secured over $5.5M in grants, including NHMRC and ARC funding. She collaborates with institutions like HMRI, John Hunter Hospital, and global teams on projects like nanoparticle-based treatments for preterm labor and uterine hemorrhage. Teaching & Leadership: She coordinates pharmacy programs, emphasizing clinical application and innovation. Her courses include Pharmacotherapeutics and Pharmacy Practice, with awards for teaching excellence (2020, 2011). Labs & Programs: Head of Therapeutic Targeting Program, University of Newcastle Director, Translational Pharmaceutics & Medical Technologies Theme (HMRI)
Prof. Dr. Mathias Christmann is a faculty member at the Institute of Chemistry and Biochemistry, Freie Universität Berlin , leading the research group in Organic Chemistry . His work focuses on strategic and methodological challenges in synthetic chemistry, particularly in total synthesis, organocatalysis, and renewable resource transformations. Position: Professor Contact: mathias.christmann@fu-berlin.de Location: Takustr. 3, Room 24.16, 14195 Berlin Research Interests include: Natural product-inspired small molecule synthesis for biological pathway modulation Minimizing C-C bond formations through selective functionalization of terpene building blocks Organocatalytic and metal-catalyzed reactions in multistep sequences Flow chemistry applications for scalable and sustainable synthesis Biological evaluation of TRPC channel agonists/antagonists for cancer therapy Publication Trends highlight expertise in total synthesis of complex terpenoids, organocatalysis for stereocontrolled reactions, flow chemistry for late-stage transformations, and TRPC4/5 channel modulation in renal cancer studies. His group pioneers asymmetric desymmetrization , photo-oxidation protocols , and electrosynthesis methods with minimal reagent waste. Advisees include PhD candidates Jan-Hendrik Dickoff , Mayar Elbendary , Nadine Kreidt , Tobias Olbrisch , Kamar Shakeri , and Zhen Wang , focusing on terpene-based drug discovery and catalytic reaction design.
